Access
To read this story in full you will need to login or make a payment (see right).
News and Views
Nature 412, 281-282 (19 July 2001) | doi:10.1038/35085665
Open Innovation Challenges
-
Direct Molecular Detection of Proteins and Nucleic Acids
This Challenge is looking for novel approaches to protein and nucleic acid detection. This is an Id...
-
Novel Approaches to Protecting Maize from Insect Damage
The Seeker is looking for novel approaches to protecting maize from insect damage. This Challenge re...
- More Challenges
- Powered by:
nature jobs
Group Leader Positions
- IMP
- Vienna Austria
Sr. Scientific Manager / Chief Scientific Manager - Discovery Bioanalytical Research and Biotransformation
- Syngene International
- Bangalore, Karnataka 560099 India
New-age drug meets resistance
Frank McCormick
Abstract
A new sort of anticancer drug, designed to suppress the wayward protein that causes a type of leukaemia, is under the spotlight. Biological detective work has now revealed how this cancer becomes resistant to the drug.
Gleevec is the anticancer drug that everybody has been talking about. Known during its development as STI-571, this drug was rushed to market so quickly that Novartis, the company that developed it, had no time to clear a new trade name.
To read this story in full you will need to login or make a payment (see right).
